Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03411915 · ClinicalTrials.gov registry record · Phase 1
A Study of XmAb®18087 in Subjects With NET and GIST
A Phase 1 study, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT03411915 is a Phase 1 study that has completed, run by Xencor. The registered enrollment target is 62 participants.
The verdict
NCT03411915, a Phase 1 study, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and regimen consisting of a first "priming" dose and escalated subsequent doses of XmAb18087; to describe safety and tolerability; to assess PK and immunogenicity; and to preliminarily assess anti-tumor activity of XmAb18087 in subjects with advanced NET or GIST. The study will enroll dosing cohorts to establish a MTD/RD and regimen in subjects with advanced NET or GIST, then enroll additional subjects into separate NET and GIST expansion cohorts to collect additional data on safety and potential efficacy of XmAb18087.
Interventions
- BIOLOGICAL XmAb18087
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2018-01-22 |
| Est. Completion | 2021-10-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03411915
The ClinicalTrials.gov registry entry for NCT03411915 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which XmAb18087 is the first listed.
NCT03411915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03411915 about?
NCT03411915 is a clinical study titled "A Study of XmAb®18087 in Subjects With NET and GIST". This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and regimen consisting of a first "priming" dose and escalated subsequent doses of XmAb18087; to describe safety and tolerability; to assess PK and immunogenicity; and to preliminarily assess anti-tumor activity of...
What is the current status of trial NCT03411915?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2018-01-22. Estimated completion is 2021-10-26.
What interventions are being tested in trial NCT03411915?
The interventions under investigation include: XmAb18087 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03411915?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.